---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-013344"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:35:56.510947+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Capricor files BLA for deramiocel in DMD cardiomyopathy; reports ~$85M cash as of Sept 30

## Summary
- BLA for deramiocel filed Oct 2024 seeking full approval for DMD cardiomyopathy; full submission by year-end 2024.
- HOPE-2/OLE data vs natural history supports BLA; HOPE-3 Cohorts A+B combined as post-approval study, Cohort A unblinding paused.
- StealthX SARS-CoV-2 vaccine selected for Project NextGen; manufacturing ongoing, delivery to NIAID by end-2024.
- Private placement to Nippon Shinyaku: 2.8M shares at $5.36 for ~$15M; ATM sales: 5.5M shares at $9.84 avg for ~$53.9M.
- Preliminary cash balance ~$85M as of Sept 30, 2024.

## SEC filing metadata
- accession: 0001558370-24-013344
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024013344/0001558370-24-013344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024013344/capr-20241016x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-013344
- JSON: https://secwatch.observer/filing/0001558370-24-013344.json
- Plain text: https://secwatch.observer/filing/0001558370-24-013344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.